SCHEMBL14429441

SCHEMBL14429441

CC(C)C1(C)SC(N[C@@H](C)c2cccs2)=NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.39
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
IDH1 O75874 2/20 0.35
MAPK1 P28482 1/20 0.33
MAPT P10636 2/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 1/20 0.32
PKM P14618 1/20 0.32
MC4R P32245 1/20 0.32
ALOX5 P09917 1/20 0.31
GAA P10253 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
TSHR P16473 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14429479 1.00 EGFR (0.39) EGFRKMT2AMEN1IDH1MAPK1
SCHEMBL14429487 1.00 EGFR (0.39) EGFRKMT2AMEN1IDH1MAPK1
SCHEMBL5463155 0.81 KMT2A (0.41) EGFRKMT2AMEN1IDH1MAPK1
SCHEMBL10249619 0.81 KMT2A (0.41) EGFRKMT2AMEN1IDH1MAPK1
SCHEMBL14429480 0.80 KMT2A (0.36) EGFRKMT2AMEN1IDH1MAPK1
SCHEMBL10249848 0.80 EGFR (0.36) EGFRKMT2AMEN1IDH1MAPK1
SCHEMBL1606574 0.80 LMNA (0.44) KMT2AMEN1IDH1MAPK1LMNA
SCHEMBL1605156 0.80 LMNA (0.44) KMT2AMEN1IDH1MAPK1LMNA
SCHEMBL1605943 0.80 LMNA (0.44) KMT2AMEN1IDH1MAPK1LMNA
SCHEMBL1605158 0.80 LMNA (0.44) KMT2AMEN1IDH1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
WO-2007061661-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 EGFR 4868/4885KMT2A 3245/4885MEN1 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.